...
首页> 外文期刊>Critical reviews in oncology/hematology >Salivary biomarkers in the diagnosis of breast cancer: A review
【24h】

Salivary biomarkers in the diagnosis of breast cancer: A review

机译:唾液生物标志物在乳腺癌的诊断中:综述

获取原文
获取原文并翻译 | 示例
           

摘要

Salivary biomarkers could be helpful to characterize breast cancer. Therefore, this review was performed to evaluate the capability of salivary biological markers in the diagnosis and monitoring of breast cancer. Studies were eligible for inclusion if they assessed the potential diagnostic value or other discriminatory properties of biological markers in saliva of patients with breast cancer. The search was performed in six electronic databases (Cochrane, LILACS, PubMed, Science Direct, Scopus, Web of Science). In addition the biomarkers were classified according to their potential clinical application. We identified 567 pertinent studies, of which 13 met the inclusion criteria. Combined biomarker approaches demonstrated better ability to predict breast cancer patients than individual biomarkers. As single biomarlcer, namely proline, reported great capacity in both early and late stage breast cancer diagnosis. Taurine showed interesting capability to identify early breast cancer individuals. Furthermore, valine also demonstrated excellent diagnostic test accuracy for advanced stages of breast cancer. Only seven studies reported sensitivity and specificity (Zhang et al., 2010; Streckfus et al., 2000a; Brooks et al., 2008; Cheng et al., 2015; Bigler et al., 2002; Zhong et al., 2016; Streckfus, 2009), which varied considerably from 50% to 100%, and from 51% to 97%, respectively. In general, salivary biomarkers identified advanced stages of breast cancer better than early stages. There is currently limited evidence to confirm the putative implementation of salivary biomarkers as diagnostic tools for breast cancer. However, current review provides new research directions. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
机译:唾液生物标志物可能有助于表征乳腺癌。因此,进行了本综述以评估唾液生物标志物在乳腺癌诊断和监测中的能力。如果他们评估了乳腺癌患者唾液中的生物学标志物的潜在诊断价值或其他鉴别性质,则研究有资格包容。搜索是在六个电子数据库(Cochrane,Lilacs,PubMed,Science,Scopus,Science)中进行的。此外,生物标志物根据其潜在的临床应用进行分类。我们确定了567项相关研究,其中13符合纳入标准。合并的生物标志物方法表明了预测乳腺癌患者的能力而不是单个生物标志物。作为单一生物摩托,即脯氨酸,据报道,早期和晚期乳腺癌诊断中的巨大能力。牛磺酸表现出有趣的能力来鉴定早期乳腺癌个体。此外,缬氨酸还表明了乳腺癌的高级阶段的优异诊断测试精度。只有七项研究报告了敏感性和特异性(Zhang等,2010; Streckfus等,2000A; Brooks等,2008; Chenget Al。,2015; Bigler等,2002; Zhonget Al。,2016; STRECKFUS,2009年),其各大于50%至100%,分别为51%至97%。一般来说,唾液生物标志物鉴定了比早期阶段更好的乳腺癌的先进阶段。目前有有限的证据证实了唾液生物标志物的推定实施作为乳腺癌的诊断工具。但是,当前的审查提供了新的研究方向。 (c)2016 Elsevier Ireland Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号